These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 33870746)
1. Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry. Scholle MD; Liu C; Deval J; Gurard-Levin ZA SLAS Discov; 2021 Jul; 26(6):766-774. PubMed ID: 33870746 [TBL] [Abstract][Full Text] [Related]
2. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry. Pearson LA; Green CJ; Lin D; Petit AP; Gray DW; Cowling VH; Fordyce EAF SLAS Discov; 2021 Jul; 26(6):749-756. PubMed ID: 33724070 [TBL] [Abstract][Full Text] [Related]
3. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Basu S; Mak T; Ulferts R; Wu M; Deegan T; Fujisawa R; Tan KW; Lim CT; Basier C; Canal B; Curran JF; Drury LS; McClure AW; Roberts EL; Weissmann F; Zeisner TU; Beale R; Cowling VH; Howell M; Labib K; Diffley JFX Biochem J; 2021 Jul; 478(13):2481-2497. PubMed ID: 34198328 [TBL] [Abstract][Full Text] [Related]
4. A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex. Khalili Yazdi A; Li F; Devkota K; Perveen S; Ghiabi P; Hajian T; Bolotokova A; Vedadi M SLAS Discov; 2021 Jul; 26(6):757-765. PubMed ID: 33874769 [TBL] [Abstract][Full Text] [Related]
5. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2. Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769 [TBL] [Abstract][Full Text] [Related]
6. Activation of the SARS-CoV-2 NSP14 3'-5' exoribonuclease by NSP10 and response to antiviral inhibitors. Riccio AA; Sullivan ED; Copeland WC J Biol Chem; 2022 Jan; 298(1):101518. PubMed ID: 34942146 [TBL] [Abstract][Full Text] [Related]
7. New targets for drug design: importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2. Saramago M; Bárria C; Costa VG; Souza CS; Viegas SC; Domingues S; Lousa D; Soares CM; Arraiano CM; Matos RG FEBS J; 2021 Sep; 288(17):5130-5147. PubMed ID: 33705595 [TBL] [Abstract][Full Text] [Related]
8. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease. Canal B; McClure AW; Curran JF; Wu M; Ulferts R; Weissmann F; Zeng J; Bertolin AP; Milligan JC; Basu S; Drury LS; Deegan TD; Fujisawa R; Roberts EL; Basier C; Labib K; Beale R; Howell M; Diffley JFX Biochem J; 2021 Jul; 478(13):2445-2464. PubMed ID: 34198326 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification. Baddock HT; Brolih S; Yosaatmadja Y; Ratnaweera M; Bielinski M; Swift LP; Cruz-Migoni A; Fan H; Keown JR; Walker AP; Morris GM; Grimes JM; Fodor E; Schofield CJ; Gileadi O; McHugh PJ Nucleic Acids Res; 2022 Feb; 50(3):1484-1500. PubMed ID: 35037045 [TBL] [Abstract][Full Text] [Related]
10. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. Narayanan N; Nair DT Int J Biol Macromol; 2021 Jan; 168():272-278. PubMed ID: 33309661 [TBL] [Abstract][Full Text] [Related]
11. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19. Perveen S; Khalili Yazdi A; Devkota K; Li F; Ghiabi P; Hajian T; Loppnau P; Bolotokova A; Vedadi M SLAS Discov; 2021 Jun; 26(5):620-627. PubMed ID: 33423577 [TBL] [Abstract][Full Text] [Related]
12. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. Kasprzyk R; Spiewla TJ; Smietanski M; Golojuch S; Vangeel L; De Jonghe S; Jochmans D; Neyts J; Kowalska J; Jemielity J Antiviral Res; 2021 Sep; 193():105142. PubMed ID: 34303749 [TBL] [Abstract][Full Text] [Related]
13. Utilization of the EpiMed Coronabank Chemical Collection to identify potential SARS-CoV-2 antivirals: in silico studies targeting the nsp14 ExoN domain and PL Liang JJ; Pitsillou E; Lau HLY; Mccubbery CP; Gan H; Hung A; Karagiannis TC J Mol Graph Model; 2024 Sep; 131():108803. PubMed ID: 38815531 [TBL] [Abstract][Full Text] [Related]
14. Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target. Tahir M J Med Virol; 2021 Jul; 93(7):4258-4264. PubMed ID: 33837972 [TBL] [Abstract][Full Text] [Related]
15. Development of a Novel Label-Free and High-Throughput Arginase-1 Assay Using Self-Assembled Monolayer Desorption Ionization Mass Spectrometry. Scholle MD; Gurard-Levin ZA SLAS Discov; 2021 Jul; 26(6):775-782. PubMed ID: 33754845 [TBL] [Abstract][Full Text] [Related]
16. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase. Ahmed-Belkacem R; Sutto-Ortiz P; Guiraud M; Canard B; Vasseur JJ; Decroly E; Debart F Eur J Med Chem; 2020 Sep; 201():112557. PubMed ID: 32563813 [TBL] [Abstract][Full Text] [Related]